The role of mTOR in the management of solid tumors: An overview期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

The role of mTOR in the management of solid tumors: An overview

Authors:	Alex S. Strimpakos Eleni M. Karapanagiotou M. Wasif Saif Kostas N. Syrigos

Affiliation:	1. Department of Medicine, Royal Marsden Hospital, Downs Road, Surrey SM2 5PT, UK;2. Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Building Z, 152 Mesogion Avenue, 115 27 Athens, Greece;3. Yale Cancer Center, Yale University School of Medicine, 310 Cedar St. P.O. Box 208023, New Haven, CT 06520-8023, USA

Abstract:

Keywords:	ALT, alanine transferase AMPK, adenosine monophosphate-dependent protein kinase AP23573, deferolimus ATP, adenosine 5&prime -triphosphate BRRS, Bannayan&ndash Riley&ndash Ruvalcaba syndrome BSC, best supportive care BV, bevacizumab CBR, clinical benefit response CCC, cholangiocellular carcinoma CCI-779, temsirolimus CD, Cowden&rsquo s disease CDK, cyclin-dependent kinase CR, complete response CRC, colorectal cancer CT, computed tomography DLTs, dose limiting toxicities DRR, dominant rapamycin resistant (gene) E, erlotinib 4E-BP1, 4E binding protein 1 EGFR, epidermal growth factor receptor eIF4E, eukaryotic initiation factor 4E EV, everolimus FAT domain, FRAP-ATM-TRRAP FATC, fat domain close to the C-terminus FGF, fibroblast growth factor FK 506, tarcolimus FOXO, Forkhead box protein O FRAP, FKBP12-rapamycin-associated protein FRB, FKB12 rapamycin binding protein GAP, GTPase activating protein GBM, glioblastoma multiforme GSK-3, glycogen synthase kinase-3 HCC, hepatocellular carcinoma HEAT, Huntingtin, EF3, A subunit of PP2A, TOR HIF-1, hypoxia inducible factor 1 HNSCC, head and neck squamous cell carcinomas IFN-A, interferon alpha IGF, insulin growth factor IGFR, insulin growth factor receptor IRS-1, insulin receptor substrate 1 LGNET, low grade neuroendocrine tumor LOH, loss of heterozygosity MDM2, murine double minute 2 MDT, maximum tolerated dose mLST8, mammalian lethal with SEC 13 mRCC, metastatic renal cell carcinoma MRI, magnetic resonance imaging mSIN1, mammalian stress-activated protein kinase interacting protein 1 mTOR, mammalian target of rapamycin mTORC1-2, mTOR complex 1 and 2 NSCLC, non-small cell lung cancer ORR, overall response rate OS, overall survival PDGFRβ, platelet derived growth factor beta PDK1, phosphoinositide-dependent protein kinase1 PFS, progression free survival PHAS-I, initiation of translation factor 4E-BP1 PIKK, phosphatidylinositol kinases PI3K, phosphoinositide 3-kinase PI3KKC3, PI3K class III PIP₂, phosphatidylinositol (4,5)-biphosphate PIP₃, phosphatidylinositol (3,4,5)-triphosphate PJS, Peutz&ndash Jeghers syndrome PKB, protein kinase B PKCa, protein kinase C alpha PR, partial response PRAS40, proline rich Akt substrate 40 kDa pRB, retinoblastoma protein PRR5, proline rich protein 5 PTEN, phosphatase and tensin homologue deleted on chromosome 10 RAD001, everolimus Raptor, regulatory associated protein of mTOR RCC, renal cell carcinoma REDD1/2, regulated in development and DNA damage 1 and 2 raptor, regulatory associated protein of mTOR Rheb, Ras homologue enriched in brain Richtor, rapamycin insensitive companion of mTOR RTK, receptor tyrosine kinase SCH66336, farnesyl transferase inhibitor lorafarnib SD, stable disease S6K1, S6 protein kinase 1 SSCP/HD, single-strand conformational polymorphism/heteroduplex STS, soft tissue sarcomas TOP, terminal oligopyrimidine TSC ½ , tuberous sclerosis complex 1 and 2 TTP, time to progression VEGF, vascular endothelial factor receptor
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏